Prospects for B-cell-targeted therapy in autoimmune disease (Q35930307)

11 August 2017

1 reference

title

Prospects for B-cell-targeted therapy in autoimmune disease (English)

1 reference

11 August 2017

1 reference

Edwards JC

1

1 reference

PubMed ID

15509628

11 August 2017

Cambridge G

series ordinal

2

1 reference

11 August 2017

27 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

44

1 reference

11 August 2017

2

1 reference

11 August 2017

151-156

1 reference

ON THE OCCURRENCE OF A FACTOR IN HUMAN SERUM ACTIVATING THE SPECIFIC AGGLUTINATION OF SHEEP BLOOD CORPUSCLES

11 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Clinical applications of anti-CD20 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Rituximab: perspective on single agent experience, and future directions in combination trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

B lymphocyte depletion therapy with rituximab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

How important are T cells in chronic rheumatoid synovitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Michael Mason Prize Essay 1995. Complement, immune complexes and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

The role of B cells in lpr/lpr-induced autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Differential distribution of Fc gamma RIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Interstitial pneumonitis related to rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH446

10.1093/RHEUMATOLOGY/KEH446

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15509628